← Back to Search

Exercise Program for Chronic Kidney Disease (ESTEEM-VIDA Trial)

Phase 2
Recruiting
Led By Baback Roshanravan, MD MS MSPH
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Moderate-severe CKD determined by estimated glomerular filtration rate (eGFR) <60ml/min per 1.73m2
No history chronic treatment with dialysis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

ESTEEM-VIDA Trial Summary

This trial is studying how well a combined resistance training and aerobic exercise program works compared to a health education program in improving physical function in people with kidney dysfunction.

Who is the study for?
This trial is for adults aged 30-75 with moderate to severe chronic kidney disease (CKD) who are not on dialysis and lead a sedentary lifestyle. They must have an eGFR <60ml/min per 1.73m2, not be taking certain medications that affect mitochondria or blood clotting, and cannot have serious heart conditions or other health issues that would make exercise unsafe.Check my eligibility
What is being tested?
The study tests whether combined resistance training and aerobic exercise via videoconferencing can improve mitochondrial function and physical performance in CKD patients compared to those receiving only health education. It aims to understand how exercise affects muscle metabolism in CKD without dialysis.See study design
What are the potential side effects?
While the intervention primarily involves physical activity which typically has benefits like improved fitness, potential side effects may include typical exercise-related injuries or discomfort such as muscle strains, joint pain, or fatigue.

ESTEEM-VIDA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney function is reduced, with an eGFR under 60.
Select...
I have never been on long-term dialysis.
Select...
I am between 30 and 75 years old.

ESTEEM-VIDA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Indium
Quadriceps muscle work efficiency
Secondary outcome measures
Change in Systemic oxidative stress (markers of arachidonic acid peroxidation)
Change in aerobic capacity (VO2max) (ml/kg/min)
Change in physical performance
+16 more
Other outcome measures
Walking economy during 6 minute walk

ESTEEM-VIDA Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Combined Aerobic and Resistance ExerciseExperimental Treatment1 Intervention
Exercise will be supervised by exercise trainers 3 days per week for 12 weeks via videoconferencing. Each session will start at 30 minutes in duration and include either high-intensity interval targeting a relative perceived exertion (RPE) of greater than 14 (on a scale of 6-20) or strength training (RPE 12-14) or power walking (RPE 12-14). Each 1 week of supervised sessions will alternate with 1 week of self-directed sessions with mid-week trainer check-in.
Group II: Usual CareActive Control1 Intervention
The control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a "Go4Life Workout to go" sample exercise routing created by the national institutes on aging (NIA).

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
911 Previous Clinical Trials
4,709,474 Total Patients Enrolled
Baback Roshanravan, MD MS MSPHPrincipal InvestigatorUC Davis
Javier Lopez, MDPrincipal InvestigatorUC Davis Department of Medicine/Division of Cardiology
1 Previous Clinical Trials
225 Total Patients Enrolled

Media Library

Combined Aerobic and Resistance Exercise via videoconferencing Clinical Trial Eligibility Overview. Trial Name: NCT02923063 — Phase 2
Chronic Kidney Disease Research Study Groups: Combined Aerobic and Resistance Exercise, Usual Care
Chronic Kidney Disease Clinical Trial 2023: Combined Aerobic and Resistance Exercise via videoconferencing Highlights & Side Effects. Trial Name: NCT02923063 — Phase 2
Combined Aerobic and Resistance Exercise via videoconferencing 2023 Treatment Timeline for Medical Study. Trial Name: NCT02923063 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the numerical scope of enrollment for this medical research project?

"Yes, according to clinicaltrials.gov, this research project is currently looking for participants. Its initial post date was January 16th 2020 with the latest update occurring on April 7th 2022. 45 patients are needed from a single location for enrollment in the study."

Answered by AI

Are there any vacancies left in this research study for participants?

"Clinicialtrials.gov states that the recruitment process for this study is still ongoing, having first started on January 16th 2020 and being updated most recently on April 7th 2022."

Answered by AI

Are individuals aged 25 and over eligible to participate in this experiment?

"This medical research is recruiting patients between the ages of 30 and 75."

Answered by AI

What are the fundamental aims of this experiment?

"Over the course of 12 weeks, trial participants' Quadriceps muscle work efficiency will be monitored and assessed as the primary outcome. As secondary outcomes, researchers have selected Lubben Social Network Scale (a self-reported social engagement survey), Total Work (total kilojoules performed on a cycle ergometer), and Kidney Disease and Quality of Life (KDQOL-SF™ 1.3; a self-reported kidney health questionnaire)."

Answered by AI

Am I eligible to be a participant in this investigation?

"This trial seeks 45 volunteers with diabetic kidney disease, hgba1c below 8.5, and aged between 30 to 75 years old that must meet the following conditions: moderate-severe CKD as judged by eGFR <60ml/min per 1.73m2, no history of chronic dialysis treatment, self-reported limited amounts of structured endurance exercise (EE) or resistance exercise (RE), perceived increased heart rate or rapid breathing during EE sessions leading to sweating and muscular fatigue experienced in RE activities lasting up to 60 minutes within a year prior to study entry; persons using biking for transportation purposes on more than one day"

Answered by AI

Has the FDA sanctioned Combined Aerobic and Resistance Exercise via videoconferencing for use in clinical settings?

"The safety of Combined Aerobic and Resistance Exercise through videoconferencing has been deemed a 2 due to the lack of empirical evidence regarding efficacy, but some data exists in regards to safety."

Answered by AI
~9 spots leftby Apr 2025